@entity1 undergoing total hip replacement are at high risk of developing @entity1211 . The 6th ACCP Consensus Conference on Antithrombotic Therapy identified two effective prophylactic methods; low molecular weight heparins (LMWH) and oral anticoagulants. However, two key issues remain controversial. The relative efficacy and safety of prophylaxis initiated pre operatively and post operatively and the optimum duration of prophylaxis. Clinical practice has diverged in North America and Europe as to the appropriate time to administer prophylaxis. This treatment is given pre-operatively in Europe and post-operatively in North America. A number of recent studies have demonstrated that an effective antithrombotic agent administered either immediately before or after surgery may be more effective than current practice. The use of LMWH for extended thromboprophylaxis is supported by convincing data. Clinical trials have demonstrated a significant benefit of @entity23868 in the prevention of @entity1211 in major orthopaedic surgery. A direct @entity556 inhibitor given sc. followed by oral administration was found to be as effective and safe as LMWH for the prophylaxis of @entity1150 ( @entity1150 ) following major hip or knee surgery.

Critical appraisal of current antithrombotic trials in XXXX undergoing total hip replacement.

@entity1 :: ('9606', 'Species') :: ['Patients'] @entity23868 :: ('CHEBI:35369', 'Chemical') :: ['pentasaccharide'] @entity556 :: ('2147', 'Gene') :: ['thrombin'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis', 'DVT'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism']
@entity1 :: (9606,Species) :: ['patients']
